a 20-year-old man
anti-glomerular basement membrane (anti-GBM) disease, an autoimmune attack on the kidneys, which started after a dental infection and caused rapidly worsening kidney failure
He first got the standard treatment of plasmapheresis (filtering the blood), corticosteroids, and cyclophosphamide, but his kidney function kept getting worse. Doctors then added obinutuzumab, a monoclonal antibody that clears out B immune cells, given as a single 500 mg dose into a vein. His antibody levels cleared within 1 month. He got his kidney function partly back and was off dialysis by 3 months, settling into stable stage 3 chronic kidney disease at 5 months.
In one young man whose severe anti-GBM kidney disease kept getting worse on standard treatment, adding a single dose of the B-cell drug obinutuzumab was followed by his coming off dialysis and settling into stable stage 3 CKD.
- Anti-GBM disease is a rare condition where the immune system attacks the kidneys, and here it started after a dental infection.
- The usual treatment of plasmapheresis, steroids, and cyclophosphamide was not enough on its own, because his kidney function kept dropping.
- Doctors added one 500 mg IV dose of obinutuzumab, a drug that clears out the B immune cells that make the harmful antibodies.
- His anti-GBM antibody levels cleared within 1 month, and he was off dialysis by 3 months.
- At the 5-month check his kidney function was partly recovered and holding steady at stage 3 CKD, even though his starting signs pointed to a poor outcome.
Why it might work
In anti-GBM disease, B immune cells make antibodies that attack the filtering membrane inside the kidneys. Plasmapheresis pulls those antibodies out of the blood and steroids plus cyclophosphamide calm the immune system, but they may not fully stop the cells that keep making new antibodies. Obinutuzumab targets and clears out those B cells directly, so the body makes fewer new attacking antibodies. In this case, wiping out the B cells lined up with the antibody levels dropping to clear within a month, which the authors suggest gave the kidneys a chance to partly recover.
The honest limits
- This is a single patient (n=1), so it cannot tell you how often this works or in whom.
- There was no comparison group, so we cannot know if he would have recovered anyway from the standard treatment given more time.
- Stage 3 CKD is based on estimated kidney function, and the abstract does not give his exact GFR number or how it was measured.
- Follow-up was only 5 months, so the abstract does not report whether the improvement lasted longer or whether infections or other side effects appeared.
- Is my type of kidney disease one where a B-cell drug like obinutuzumab could ever be considered, or is my situation different?
- What are the risks of adding a B-cell-depleting drug, such as infections, and how would you watch for them?
- Since this is based on just one patient, what stronger evidence exists before a treatment like this would be tried for me?